Tower Research Capital LLC (Trc) Cellectar Biosciences, Inc. Transaction History

Tower Research Capital LLC (Trc)

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$3.5 - $6.9 $28,203 - $55,600	8,058 Added 95.28%	16,515 $7,000
Q1 2022 May 12, 2022	BUY	$4.6 - $7.8 $35,438 - $60,091	7,704 Added 1023.11%	8,457 $6,000
Q4 2021 Feb 14, 2022	BUY	$6.1 - $10.2 $4,593 - $7,680	753 New	753 $0
Q2 2021 Aug 16, 2021	SELL	$11.8 - $18.2 $181,873 - $280,516	-15,413 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$15.2 - $25.0 $234,277 - $385,325	15,413 New	15,413 $25,000
Q4 2020 Feb 16, 2021	SELL	$11.2 - $27.7 $62,932 - $155,646	-5,619 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$10.6 - $16.6 $22,143 - $34,677	-2,089 Reduced 27.1%	5,619 $7,000
Q2 2020 Aug 13, 2020	BUY	$10.3 - $17.3 $79,392 - $133,348	7,708 New	7,708 $10,000

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $13M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.